Core Viewpoint - Bausch + Lomb Corporation is under investigation for potential violations of federal securities laws and unlawful business practices following a product recall and subsequent stock price drop [1][2]. Group 1: Product Recall and Impact - On March 27, 2025, Bausch + Lomb announced a voluntary recall of intraocular lenses from its enVista platform due to reports of toxic anterior segment syndrome (TASS), which is a complication associated with cataract surgery [2]. - The recall has raised short-term concerns regarding product safety and may lead to increased regulatory scrutiny [2]. - Following the recall announcement, Bausch + Lomb's stock price fell by $1.50 per share, representing a 10.6% decrease, closing at $15.00 on the same day [2]. Group 2: Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Bausch + Lomb on behalf of its stockholders, focusing on possible violations of federal securities laws [1]. - The law firm is reaching out to long-term stockholders who may have suffered losses or have information related to the claims [3].

Core Viewpoint - Bausch + Lomb Corporation is under investigation for potential securities fraud and unlawful business practices following significant financial losses and a product recall [1][3]. Financial Performance - Bausch + Lomb reported an adjusted net loss of $54 million for Q1 2025, a stark contrast to an adjusted net income of $24 million in Q1 2024 [3]. - The company has revised its full-year growth outlook to a range of 4.5% to 6.5% year-over-year, down from a previous guidance of 5.5% to 7.5% [3]. Stock Price Movement - Following the announcement of a voluntary recall of intraocular lenses due to toxic anterior segment syndrome, Bausch + Lomb's stock price dropped by $1.54 per share, or 9.83%, closing at $14.13 on March 28, 2025 [2]. - After the release of Q1 2025 financial results, the stock price fell further by $2.16 per share, or 15.74%, closing at $11.56 on April 30, 2025 [4].